DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Oculus Innovative Sciences, Inc. 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

 Key Statistics


Email: hr@oculusis.com
Ownership: Public

Web Site: Oculus Innovative Sciences, Inc.
Employees:
Symbol: OCLS
 









 Company News
Oculus Innovative Sciences, Inc. (OCLS) Reports Financial Results For The Second Quarter Of Fiscal Year 2015 11/14/2014 10:34:41 AM
Oculus Innovative Sciences, Inc. (OCLS) Commercializes Microcyn®-Based Solution And Hydrogel For Treatment Of Mild-To-Moderate Acne In Europe 11/11/2014 10:20:04 AM
Oculus Innovative Sciences, Inc. (OCLS) Receives European CE Mark For New Microcyn®-Based Scar Management Hydrogel 11/4/2014 10:04:58 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Second Quarter 2015 Financial Results And Conference Call 10/30/2014 7:53:14 AM
Oculus Innovative Sciences, Inc. (OCLS) Receives European CE Mark for New Microcyn®-Based Atopic Dermatitis Hydrogel 10/30/2014 7:39:55 AM
Oculus Innovative Sciences, Inc. (OCLS) Strengthens Intellectual Property Portfolio With Allowance Of Four New Patents For Microcyn® Technology 9/16/2014 1:14:03 PM
Oculus Innovative Sciences, Inc. (OCLS) Introduces Microcyn®-Based Over-The-Counter Advanced Scar Management Hydrogel In United States 9/10/2014 8:26:44 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $3.4 Million And Net Loss Of $70,000 For First Quarter Of Fiscal 2015 8/8/2014 8:50:21 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal First Quarter 2015 Financial Results And Conference Call 7/24/2014 10:35:52 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 7/9/2014 9:14:50 AM
12345678910...